|Table of Contents|

Prognostic analysis in male breast cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 02
Page:
213-216
Research Field:
Publishing date:

Info

Title:
Prognostic analysis in male breast cancer patients
Author(s):
Wang Jizhao1; Sun Yuchen2; Qu Jingkun1; Yan Yan1; Liu Lin1; Lu Ning1; Wang Jiansheng1
1.The Second Department of Thoracic Surgery;2.Department of Radiation Oncology,The First Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710061,China.
Keywords:
male; breast cancer; ER; PR; HER-2; SEER database; survival analysis
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2017.02.013
Abstract:
Objective:To investigate prognostic factors and appropriate treatment in male breast cancer patients considering overall survival(OS).Methods:By Kapaln-Meier method,Log-rank test and Cox regression model to analyze contributing factors in OS about male breast cancer patients.Results:Total of 475 patients were identified from seer database,and 111 died due to breast cancer with an average OS of 40.468 months.Most patients were in 2-3 stages and have a propensity for malignancy.92.4% were ER positive,85.1%were PR positive and 76.4% were HER-2 negative.8.8% experienced metastasis:22.5% chose radiation and 88.2% underwent surgery.Single-variate log rank analysis indicated that tumor size,lymph node status,metastasis,grade,surgery,ER,PR,HER-2 significantly correlated to OS.COX regression model suggested that ER,PR were independent factors for OS.Conclusion:ER,PR were protecting factors.However,lower frequency of HER-2 in male patients suggests novel clues for TNBC patients.More positive treatment should be given for lymph node infiltrating patients,and radiation is not recommended.

References:

［1］ Sasco AJ,Lowenfels AB,Jong PPD.A meta-analysis of published case-control studies and discussion of selected aetiological factors［J］.Int J Cancer,1993,53(4):538-549.
［2］Liu XL,Liu FF,Zheng Yi,et al.Clinicopathological features and prognostic factors of male breast cancer［J］.Chin J Clin Oncol,2014,41(23):1521-1526.［刘新丽,刘芳芳,郑屹,等.男性乳腺癌临床病理特征及预后分析［J］.中国肿瘤临床,2014,41(23):1521-1526.］
［3］Brinton LA,Cook MB,Mccormack V,et al.Anthropometric and hormonal risk factors for male breast cancer:male breast cancer pooling project results［J］.J National Cancer Institute,2014,106(3):359-362.
［4］Cui F,Lu S,Liu H,et al.Progress in the pharmacotherapy of male breast cancer［J］.Chin J Clin Oncol,2015,42(21):1071-1074.［崔芳,陆苏,刘红,等.男性乳腺癌药物治疗研究进展［J］.中国肿瘤临床,2015,42(21):1071-1074.］
［5］Takagi K,Moriya T,Kurosumi M,et al.Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma:comparison with female breast carcinoma［J］.Hormones and Cancer,2013,4(1):1-11.
［6］ Dakin Hache K,Gray S,Barnes PJ,et al.Clinical and pathological correlations in male breast cancer:intratumoral aromatase expression via tissue microarray［J］.Breast Cancer Res Treat,2007,105(2):169-175.
［7］Holowatyj AN,Ruterbusch JJ,Ratnam M,et al.HER2 status and disparities in luminal breast cancers［J］.Cancer Medicine,2016,5(8):2109-2116.
［8］ Wang XX,Jiang YZ,Liu XY，et al.Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma:a population based study from SEER 18 database［J］.Oncotarget,2016,7(16):22665-22673.
［9］Tian DL,Bo HM,Yang SC,et al.Clinical analysis of male breast cancer［J］.Cancer Res Prev Treat,2006,33(11):826-828.［田大龙,柏会明,杨树成,等.男性乳腺癌术后放疗疗效分析［J］.肿瘤防治研究,2006,33(11):826-828.］
［10］ Geng C,Zhang XG,Guo F,et al.A Study of the relation between systemic blood coagulation and leukopenia in local Irradiation［J］.Practical J Cancer,2013,28(2):127-129.［耿冲,张旭光,郭峰,等.放疗局部照射中全身凝血功能与白细胞减少的关系［J］.实用癌症杂志,2013,28(2):127-129.］
［11］Ruddy KJ,Winer EP.Male breast cancer:risk factors,biology,diagnosis,treatment,and survivorship［J］.Ann Oncol,2013,24(6):1434-1443.
［12］ Fentiman IS.Male breast cancer is not congruent with the female disease［J］.Critical Reviews in Oncol Hematol,2016,101:119-124.

Memo

Memo:
国家自然科学基金（编号：81502295）
Last Update: 1900-01-01